The company has established a new venture, OncoTherics Poland SA, with the necessary expertise to progress its drug development programme through to product license approval. The Polish company has raised first investment funds and benefited from a Polish Regional Development Grant. OncoTherics Poland SA intends to list on the public markets in Poland in the near future, in order to fund its pre-clinical and clinical development programmes.
The Company has received loans from an associate company which are not repayable until all other creditors have been repaid